Skip to main content

Devgen Awarded 1.9M Euro From Flemish Government

NEW YORK, Nov. 20 (GenomeWeb News) - Devgen has been awarded a grant for 1.9 million Euro ($2.3 million) from the Flemish Government in Flanders, Belgium to develop the company's C. elegans RNAi and genetics technology for identification of mechanism of action in human drugs, the company said today.


The Flemish Institute for the Promotion of Industrial Scientific and Technological Research has awarded the grant, the company said.


Devgen's technology uses RNAi to identify functionally validated genes in the model organism C. elegans. The company has in-house programs to develop therapies for metabolic and cardiovascular diseases, as well as development of nematode- and insect-resistant crops and novel pesticides.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.